Schizophreniform Disorder

Categories: Mental diseases

Aliases & Classifications for Schizophreniform Disorder

MalaCards integrated aliases for Schizophreniform Disorder:

Name: Schizophreniform Disorder 12 74 15
Schizophreniform Disorders 54 71
Psychotic Disorders 43 71


External Ids:

Disease Ontology 12 DOID:11328
ICD9CM 34 295.4
MeSH 43 D011618
NCIt 49 C94376
SNOMED-CT 67 88975006
ICD10 32 F20.81
UMLS 71 C0033975 C0036358

Summaries for Schizophreniform Disorder

Disease Ontology : 12 A psychotic disorder that involves schizophrenia symptoms over time period of one month.

MalaCards based summary : Schizophreniform Disorder, also known as schizophreniform disorders, is related to schizophrenia 2 and avoidant personality disorder, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Schizophreniform Disorder is NRG1 (Neuregulin 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Guanfacine and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Schizophreniform disorder is a mental disorder diagnosed when symptoms of schizophrenia are present for... more...

Related Diseases for Schizophreniform Disorder

Diseases related to Schizophreniform Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 335)
# Related Disease Score Top Affiliating Genes
1 schizophrenia 2 32.0 PRODH DISC1
2 avoidant personality disorder 30.7 DRD4 DRD3 DRD2
3 tardive dyskinesia 30.4 HTR2A DRD3 DRD2 COMT
4 traumatic brain injury 30.4 DRD2 COMT BDNF
5 brain injury 30.4 DRD2 COMT BDNF
6 capgras syndrome 30.4 PRODH HTR2A
7 sexual disorder 30.3 PRL HTR2A DRD2
8 endogenous depression 30.2 HTR2A COMT BDNF
9 hyperprolactinemia 30.1 PRL HTR2A DRD4 DRD2
10 melancholia 30.0 PRL HTR2A BDNF
11 phobia, specific 29.9 PRODH COMT CGAS
12 early-onset schizophrenia 29.8 DRD2 DRD1 BDNF
13 drug psychosis 29.8 HTR2A DRD5 DRD4 DRD3 DRD2 DRD1
14 cannabis dependence 29.8 NRG1 COMT CNR1
15 sleep disorder 29.8 PRL HTR2A DRD2 BDNF
16 schizoaffective disorder 29.8 PRODH PRL HTR2A DTNBP1 DRD4 DRD3
17 borderline personality disorder 29.6 PRL HTR2A DRD2 COMT BDNF
18 dysthymic disorder 29.6 HTR2A CGAS BDNF
19 alcohol use disorder 29.5 PRODH HTR2A DRD3 DRD2 DRD1 COMT
20 social phobia 29.5 PRODH PRL DRD2 COMT CGAS
21 conduct disorder 29.4 DRD5 DRD4 DRD2 COMT
22 withdrawal disorder 29.3 DRD2 DRD1 CNR1
23 amnestic disorder 29.3 DRD2 CNR1 BDNF
24 schizotypal personality disorder 29.2 ZNF804A PRODH NRG1 DTNBP1 DRD4 DRD2
25 postpartum depression 29.2 PRL EEF1AKNMT COMT BDNF
26 mental depression 29.2 PRODH HTR2A DRD4 DRD2 DRD1 DISC1
27 post-traumatic stress disorder 29.1 NRG1 HTR2A DRD2 COMT CNR1 BDNF
28 polysubstance abuse 29.1 DRD3 DRD2 COMT CNR1
29 movement disease 29.1 DRD5 DRD4 DRD3 DRD2 DRD1
30 narcolepsy 29.0 HTR2A DRD2 DRD1 COMT BDNF
31 personality disorder 29.0 PRL HTR2A DRD4 DRD3 DRD2 COMT
32 cannabis abuse 29.0 NRG1 DRD4 DRD2 COMT CNR1 BDNF
33 obsessive-compulsive disorder 29.0 PRL HTR2A DRD4 DRD3 DRD2 DRD1
34 eating disorder 28.9 HTR2A DRD3 DRD2 COMT CNR1 BDNF
35 asperger syndrome 28.8 DISC1 COMT CNR1 BDNF
36 anorexia nervosa 28.5 PRL HTR2A DRD4 COMT CNR1 BDNF
37 bipolar i disorder 28.4 ZNF804A NRG1 HTR2A DTNBP1 DRD4 DRD3
38 mood disorder 28.4 PRODH HTR2A DRD4 DRD3 DRD2 DRD1
39 delusional disorder 28.4 PRODH HTR2A DRD5 DRD4 DRD3 DRD2
40 choreatic disease 28.4 DRD5 DRD4 DRD3 DRD2 DRD1 BDNF
41 cocaine dependence 28.4 PRL HTR2A DRD3 DRD2 DRD1 COMT
42 paranoid schizophrenia 28.4 PRL HTR2A DRD5 DISC1 COMT CNR1
43 substance-induced psychosis 28.1 HTR2A DTNBP1 DRD5 DRD4 DRD3 DRD2
44 panic disorder 28.1 PRL HTR2A DRD5 DRD4 DRD3 DRD2
45 anxiety 27.8 PRODH PRL HTR2A DRD4 DRD3 DRD2
46 body mass index quantitative trait locus 11 27.7 PRODH PRL HTR2A DRD4 DRD2 COMT
47 dystonia 27.5 PRL HTR2A DRD5 DRD3 DRD2 DRD1
48 attention deficit-hyperactivity disorder 27.3 ZNF804A PRODH PRL HTR2A DRD5 DRD4
49 substance dependence 27.2 DTNBP1 DRD5 DRD4 DRD3 DRD2 DRD1
50 alcohol dependence 27.2 PRL HTR2A DRD5 DRD4 DRD3 DRD2

Comorbidity relations with Schizophreniform Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 113)

Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Adjustment Disorder
Age-Related Hearing Loss Alzheimer Disease
Amnestic Disorder Antisocial Personality Disorder
Anxiety Aortic Valve Disease 1
Atypical Depressive Disorder Bacteremia 2
Bipolar Disorder Blepharitis
Borderline Personality Disorder Brain Cancer
Bronchitis Bronchopneumonia
Bullous Pemphigoid Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Chronic Ulcer of Skin Communicating Hydrocephalus
Conduct Disorder Conjunctivitis
Conversion Disorder Cyclothymic Disorder
Cystitis Decubitus Ulcer
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dermatomycosis
Diabetes Mellitus, Noninsulin-Dependent Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Erythematosquamous Dermatosis Esophageal Disease
Esophagitis Familial Atrial Fibrillation
Folic Acid Deficiency Anemia Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Hepatic Encephalopathy Hypertension, Essential

Graphical network of the top 20 diseases related to Schizophreniform Disorder:

Diseases related to Schizophreniform Disorder

Symptoms & Phenotypes for Schizophreniform Disorder

UMLS symptoms related to Schizophreniform Disorder:

photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances, mental and behavioral signs and symptoms, clouded consciousness, catatonic reaction

GenomeRNAi Phenotypes related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.36 PRODH
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.36 PRODH
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-172 9.36 DRD4
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.36 PRODH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.36 DRD3 PRODH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.36 DRD3 DRD4 PRODH
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.36 PRODH
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.36 PRODH

MGI Mouse Phenotypes related to Schizophreniform Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.2 BDNF CGAS CNR1 COMT DISC1 DRD1
2 homeostasis/metabolism MP:0005376 10 BDNF CGAS CNR1 COMT DISC1 DRD1
3 digestive/alimentary MP:0005381 9.8 BDNF CNR1 DRD1 DRD2 DRD3 FGA
4 integument MP:0010771 9.56 BDNF CNR1 DRD1 DRD2 DTNBP1 FGA
5 nervous system MP:0003631 9.47 BDNF CNR1 COMT DISC1 DRD1 DRD2

Drugs & Therapeutics for Schizophreniform Disorder

Drugs for Schizophreniform Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 388)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Perphenazine Approved Phase 4 58-39-9 4748
Molindone Approved Phase 4 7416-34-4 23897
Amisulpride Approved, Investigational Phase 4 71675-85-9, 53583-79-2 2159
Norepinephrine Approved Phase 4 51-41-2 439260
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 3001386
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Donepezil Approved Phase 4 120014-06-4 3152
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Memantine Approved, Investigational Phase 4 19982-08-2 4054
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
16 Perazine Approved, Investigational Phase 4 84-97-9
Pimozide Approved Phase 4 2062-78-4 16362
18 Benperidol Approved, Investigational Phase 4 2062-84-2
Fluphenazine Approved Phase 4 69-23-8 3372
20 bromperidol Approved, Investigational Phase 4 10457-90-6 2448
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
25 Coconut Approved Phase 4
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
Cinnarizine Approved, Investigational Phase 4 298-57-7 2761 1547484
Histamine Approved, Investigational Phase 4 51-45-6 774
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
Pravastatin Approved Phase 4 81093-37-0 54687
Allopurinol Approved Phase 4 315-30-0 2094
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
Pramlintide Approved, Investigational Phase 4 151126-32-8
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Amitriptyline Approved Phase 4 50-48-6 2160
Aripiprazole lauroxil Approved, Investigational Phase 4 1259305-29-7 49831411
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
Losartan Approved Phase 4 114798-26-4 3961
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
Clozapine Approved Phase 4 5786-21-0 2818
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755

Interventional clinical trials:

(show top 50) (show all 1226)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications Unknown status NCT02213887 Phase 4 Pantoprazole;Pantoprazole
2 A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine Unknown status NCT02286206 Phase 4 Clozapine
3 A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
4 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
5 Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
6 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
7 An Open-label Switch Study to Asenapine in the Early Stage of Psychosis Unknown status NCT01968161 Phase 4 Asenapine
8 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
9 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
10 Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
11 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
12 Locus Coeruleus Neuroimaging of Antipsychotic/Modafinil Interactions on Cognition in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
13 Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging Unknown status NCT02095938 Phase 4 amisulpride
14 A Multi-center, Randomized, Double Blind, Parallel, PhaseⅣ Trial to Evaluate the Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder Completed NCT02137993 Phase 4 A-prexa;Zyprexa
15 The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
16 Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder. Completed NCT00304655 Phase 4 Aripiprazole
17 Treatment of Schizophrenia and Related Disorders in Children and Adolescents Completed NCT00053703 Phase 4 Risperidone;Olanzapine (enrollment closed in this treatment);Molindone
18 Varenicline Adjunctive Treatment in Schizophrenia Completed NCT00492349 Phase 4 Varenicline;Placebo
19 An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis Completed NCT00246259 Phase 4 Risperidone long-acting injection (LAI);Oral Antipsychotic
20 Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone Completed NCT01855074 Phase 4 Risperidone
21 Optimization of Treatment and Management of Schizophrenia in Europe Completed NCT01248195 Phase 4 Amisulpride open label;6-week amisulpride double blind treatment;6-week olanzapine double blind treatment;12-week clozapine open-label treatment
22 Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia Completed NCT00103571 Phase 4 Olanzapine;Aripiprazole
23 Citalopram in First Episode Schizophrenia Completed NCT01041274 Phase 4 Citalopram;Placebo
24 The Assessment of a Weight Management Program for Treatment-Emergent Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder During Olanzapine Therapy Completed NCT00485823 Phase 4 Olanzapine Hydrochloride
25 A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression Completed NCT00034801 Phase 4 olanzapine;ziprasidone
26 Insulin Sensitivity in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Risperidone Completed NCT00190749 Phase 4 olanzapine;risperidone
27 Treatment of Major Depressive Episodes During the Course of Psychotic Disorders With Duloxetine Completed NCT00224302 Phase 4 Duloxetine
28 Efficacy and Safety of Aripiprazole in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study Completed NCT01026584 Phase 4 Aripiprazole
29 Efficacy and Safety of Paliperidone ER in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study Completed NCT01157585 Phase 4 paliperidone ER
30 Efficacy and Safety With Ziprasidone in the Treatment of First-episode Schizophrenia Spectrum Disorder: Multi-center Study Completed NCT01157559 Phase 4 Ziprasidone
31 Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence Completed NCT00215579 Phase 4 Depot Risperidone Microsphere (Consta)
32 Health Evaluation of Abilify Long-term Therapy Completed NCT00520650 Phase 4 Aripiprazole
33 A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00137020 Phase 4 ziprasidone
34 The Cognitive Effects of Risperidone and Olanzapine Completed NCT00108368 Phase 4 Risperidone;Olanzapine
35 Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder Completed NCT00100776 Phase 4 Olanzapine
36 An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease Completed NCT00095810 Phase 4 aripiprazole
37 The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00090012 Phase 4 Olanzapine;Quetiapine
38 Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia. Completed NCT00337662 Phase 4 olanzapine;risperidone;risperidone
39 A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
40 BMI Evaluation: Placebo and Active Comparator Trial of Olanzapine Zydis Pills Used Sublingually (PLATYPUS) Completed NCT00303602 Phase 4 Sublingual orally disintegrating olanzapine (SODO);Oral olanzapine
41 The Effects of Risperdal Consta on Health Care Utilization Costs in Chronically Ill Schizophrenic Patients Completed NCT00313391 Phase 4 Risperdal Consta
42 A Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder Completed NCT00649064 Phase 4 Ziprasidone
43 An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis Completed NCT00644800 Phase 4 Ziprasidone
44 Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial Completed NCT02307396 Phase 4 Olanzapine;Amisulpride;Risperidone;Haloperidol;Quetiapine;Perphenazine;Sulpiride;bromperidol;Zuclopenthixol;Thioridazine;Paliperidone;Ziprasidone;Benperidol;Fluspirilene;Pimozide;Perazine;Fluphenazine;Flupentixole;Sertindole
45 Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia Completed NCT00330551 Phase 4 Oral Risperidone;Risperidone in Long-Acting Injectable Form (Consta)
46 Agomelatine Treatment of Major Depressive Episodes in the Course of Schizophrenic Psychoses (AGOPSYCH) Completed NCT01822418 Phase 4 agomelatine
47 A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder. Completed NCT00521365 Phase 4 Quetiapine 600mg
48 Bergen Psychosis Project 2 - The Bergen-Stavanger-Innsbruck-Trondheim Study Completed NCT01446328 Phase 4 Amisulpride;Aripiprazole;Olanzapine
49 Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial Completed NCT00224315 Phase 4 ziprasidone;risperidone
50 A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence Completed NCT01015586 Phase 4 Lamotrigine;Placebo

Search NIH Clinical Center for Schizophreniform Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Acetophenazine maleate
Chlorpromazine hydrochloride
fluphenazine decanoate
Fluphenazine enanthate
Fluphenazine Hydrochloride
haloperidol decanoate
Haloperidol lactate
Loxapine hydrochloride
Loxapine Succinate
Mesoridazine besylate
Molindone Hydrochloride
Mylan brand of clozapine
Prochlorperazine Edisylate Salt
Prochlorperazine Maleate
Promazine Hydrochloride
Quetiapine fumarate
Thioridazine Hydrochloride
Thiothixene hydrochloride
Trifluoperazine hydrochloride
Triflupromazine hydrochloride
UDL brand of clozapine

Cochrane evidence based reviews: psychotic disorders

Genetic Tests for Schizophreniform Disorder

Anatomical Context for Schizophreniform Disorder

MalaCards organs/tissues related to Schizophreniform Disorder:

Brain, Testes, Heart, Pituitary, Cortex, Liver, Thyroid

Publications for Schizophreniform Disorder

Articles related to Schizophreniform Disorder:

(show top 50) (show all 554)
# Title Authors PMID Year
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. 54 61
18786813 2008
Effects of socio-demographic characteristics, premorbid functioning, and insight on duration of untreated psychosis in first-episode schizophrenia or schizophreniform disorder in Northern Malawi. 61
30706661 2019
Sex differences in event-related potential (ERP) waveforms of primary psychotic disorders: A systematic review. 61
30790596 2019
The prevalence of schizophrenia and other psychotic disorders among homeless people: a systematic review and meta-analysis. 61
31775786 2019
Informed consent and ethical reporting of research in clinical trials involving participants with psychotic disorders. 61
31247285 2019
Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort). 61
31323113 2019
Therapeutic drug monitoring of olanzapine and cytochrome P450 genotyping in non-smoking subjects. 61
31425442 2019
Insomnia and suicidal ideation in nonaffective psychosis. 61
30407600 2019
Associations between schizophrenia genetic risk, anxiety disorders and manic/hypomanic episode in a longitudinal population cohort study. 61
30472973 2019
Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale. 61
30012064 2019
[Adolescent with a schizophreniform disorder and recurrent 16p11.2 duplication]. 61
31243752 2019
Anesthesia Management of Special Patient Populations Undergoing Electroconvulsive Therapy: A Review. 61
31130568 2019
Early interventions in a US military FIRST episode psychosis program. 61
29971958 2018
Contribution of stress and coping strategies to problematic Internet use in patients with schizophrenia spectrum disorders. 61
30282059 2018
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. 61
30115598 2018
The Psychopathology of Delusion of Control According to Subjective Experience. 61
30286844 2018
Childhood adversity and cognitive function in schizophrenia spectrum disorders and healthy controls: evidence for an association between neglect and social cognition. 61
29268811 2018
A causality dilemma: ARFID, malnutrition, psychosis, and hypomagnesemia. 61
30192994 2018
Systematic review and meta-analysis found higher levels of behavioural problems in male left-behind children aged 6-11 years. 61
29280182 2018
Detection of early psychotic symptoms: Validation of the Spanish version of the "Symptom Onset in Schizophrenia (SOS) inventory". 61
29287238 2018
Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia. 61
28981811 2018
Substance abuse and gender differences in first episode psychosis: Impact on hospital readmissions. 61
28648845 2018
[Prefrontal Cortex Activity During Facial Affect Processing in Schizophrenia: Association with Clinical Symptoms and Social Cognitive Functions]. 61
30887473 2018
Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study. 61
29212505 2017
Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. 61
29064090 2017
Autopsy-proven Mirtazapine Withdrawal-induced Mania/Hypomania Associated with Sudden Death. 61
29472753 2017
Peripheral blood gene expression of acute phase proteins in people with first episode psychosis. 61
28627459 2017
Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment. 61
28347393 2017
Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder. 61
28839335 2017
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. 61
28540034 2017
Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis. 61
26980142 2016
Hypocalcemia Masquerading as Schizophreniform Disorder. 61
27833232 2016
The McLean-Harvard First-Episode Project: Early Course in 114 Cases of First-Episode Nonaffective Psychoses. 61
27232651 2016
Psychosis of epilepsy: a multifaceted neuropsychiatric disorder. 61
27322691 2016
Seropositivity of neurotropic infectious agents in first-episode schizophrenia patients and the relationship with positive and negative symptoms. 61
27287787 2016
Menstrual cycle characteristics in women with persistent schizophrenia. 61
26070315 2016
White matter alterations associated with suicide in patients with schizophrenia or schizophreniform disorder. 61
26774424 2016
Nitric Oxide's Involvement in the Spectrum of Psychotic Disorders. 61
27450675 2016
Cannabis and Alcohol Abuse Among First Psychotic Episode Inpatients. 61
28492376 2016
[Psychogenic depression and endogenous process (to the problem of reactive schizophrenia)]. 61
27240173 2016
Sex Differences in Severity, Social Functioning, Adherence to Treatment, and Cognition of Adolescents with Schizophrenia. 61
27703813 2016
Risk factor assessment and counselling for 12 months reduces metabolic and cardiovascular risk in overweight or obese patients with schizophrenia spectrum disorders: The CRESSOB study. 61
26905887 2016
Oxidative Stress and DNA Damage in Untreated First-Episode Psychosis in Adolescents. 61
27003298 2016
Comparison of the density of gamma-aminobutyric acid in the ventromedial prefrontal cortex of patients with first-episode psychosis and healthy controls. 61
27199525 2015
Dorsal striatal volumes in never-treated patients with first-episode schizophrenia before and during acute treatment. 61
26441006 2015
Two rare deletions upstream of the NRXN1 gene (2p16.3) affecting the non-coding mRNA AK127244 segregate with diverse psychopathological phenotypes in a family. 61
26563496 2015
The mRNA Expression Status of Dopamine Receptor D2, Dopamine Receptor D3 and DARPP-32 in T Lymphocytes of Patients with Early Psychosis. 61
26561806 2015
Asenapine versus placebo for schizophrenia. 61
26599405 2015
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. 61
26338693 2015
Predictors of rapid reincarceration in mentally ill young offenders. 61
26405242 2015

Variations for Schizophreniform Disorder

Expression for Schizophreniform Disorder

Search GEO for disease gene expression data for Schizophreniform Disorder.

Pathways for Schizophreniform Disorder

Pathways related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
5 12.17 DRD5 DRD2 DRD1 BDNF
7 12.08 DRD5 DRD4 DRD3 DRD2 DRD1
Show member pathways
12.02 DRD5 DRD4 DRD2 DRD1
Show member pathways
Show member pathways
11.74 DRD4 DRD3 DRD2
11 11.68 HTR2A DRD4 DRD3 CNR1
12 11.67 HTR2A DRD2 DRD1
Show member pathways
14 11.31 DRD2 DRD1 BDNF
15 10.8 DRD5 DRD3 DRD2 DRD1
Show member pathways

GO Terms for Schizophreniform Disorder

Cellular components related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.24 ZNF804A NRG1 HTR2A GRM3 FGA DTNBP1
2 integral component of plasma membrane GO:0005887 10.09 NRG1 HTR2A GRM3 DRD5 DRD4 DRD3
3 dendrite GO:0030425 9.93 HTR2A DRD4 DRD2 DRD1 COMT BDNF
4 postsynaptic density GO:0014069 9.85 GRM3 DTNBP1 DRD2 DISC1
5 postsynaptic membrane GO:0045211 9.81 GRM3 DTNBP1 DISC1 COMT
6 dendritic spine GO:0043197 9.73 ZNF804A GRM3 DTNBP1 DRD2 DRD1 COMT
7 GABA-ergic synapse GO:0098982 9.72 NRG1 DRD3 DRD2 DRD1 CNR1
8 integral component of postsynaptic membrane GO:0099055 9.71 HTR2A GRM3 DRD2 DRD1
9 synaptic vesicle membrane GO:0030672 9.7 DTNBP1 DRD3 DRD2
10 ciliary membrane GO:0060170 9.67 DRD5 DRD2 DRD1
11 non-motile cilium GO:0097730 9.65 DRD5 DRD2 DRD1
12 glutamatergic synapse GO:0098978 9.61 NRG1 HTR2A GRM3 DTNBP1 DRD4 DRD3
13 integral component of presynaptic membrane GO:0099056 9.55 HTR2A GRM3 DRD2 DRD1 CNR1
14 dopaminergic synapse GO:0098691 9.54 DRD3 DRD2
15 axon GO:0030424 9.32 ZNF804A NRG1 HTR2A GRM3 DTNBP1 DRD2

Biological processes related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 PRL HTR2A GRM3 DRD5 DRD4 DRD3
2 G protein-coupled receptor signaling pathway GO:0007186 10.26 HTR2A GRM3 DRD5 DRD4 DRD3 DRD2
3 response to drug GO:0042493 10.08 HTR2A DRD3 DRD2 DRD1 COMT
4 chemical synaptic transmission GO:0007268 10.01 HTR2A GRM3 DRD5 DRD4
5 positive regulation of neuron projection development GO:0010976 9.97 ZNF804A DISC1 CNR1 BDNF
6 cellular calcium ion homeostasis GO:0006874 9.95 HTR2A DRD5 DRD4 DRD3
7 locomotory behavior GO:0007626 9.93 NRG1 DRD3 DRD2 DRD1
8 memory GO:0007613 9.92 HTR2A DRD1 CNR1 BDNF
9 response to ethanol GO:0045471 9.91 DRD3 DRD2 CNR1
10 learning GO:0007612 9.88 DRD3 DRD1 COMT
11 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.88 HTR2A DRD4 DRD1 CNR1
12 visual learning GO:0008542 9.87 DRD3 DRD2 DRD1
13 synapse assembly GO:0007416 9.87 NRG1 DRD2 DRD1 BDNF
14 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.86 DRD3 DRD2 DRD1
15 regulation of synaptic vesicle exocytosis GO:2000300 9.86 HTR2A DTNBP1 DRD2 DRD1
16 regulation of synaptic transmission, glutamatergic GO:0051966 9.84 GRM3 DISC1 CNR1
17 associative learning GO:0008306 9.84 DRD5 DRD2 DRD1
18 response to morphine GO:0043278 9.83 DRD3 DRD2 CNR1
19 regulation of dopamine secretion GO:0014059 9.83 HTR2A DTNBP1 DRD3 DRD2
20 arachidonic acid secretion GO:0050482 9.82 DRD4 DRD3 DRD2
21 negative regulation of adenylate cyclase activity GO:0007194 9.81 GRM3 DRD3 DRD2
22 negative regulation of protein secretion GO:0050709 9.8 DRD4 DRD3 DRD2
23 temperature homeostasis GO:0001659 9.8 HTR2A DRD2 DRD1
24 negative regulation of blood pressure GO:0045776 9.8 DRD5 DRD3 DRD2 CNR1
25 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.8 DRD5 DRD3 DRD2 DRD1 CNR1
26 negative regulation of voltage-gated calcium channel activity GO:1901386 9.78 DRD4 DRD3 DRD2
27 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.78 DRD5 DRD3 DRD2 DRD1
28 prepulse inhibition GO:0060134 9.77 DRD3 DRD2 DRD1
29 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.77 HTR2A DRD3 DRD2
30 behavioral response to ethanol GO:0048149 9.76 DRD4 DRD3 DRD2
31 positive regulation of kinase activity GO:0033674 9.73 HTR2A DRD4
32 negative regulation of cytosolic calcium ion concentration GO:0051481 9.73 DRD3 DRD2
33 transmission of nerve impulse GO:0019226 9.73 DRD5 DRD1
34 long-term synaptic depression GO:0060292 9.73 DRD5 DRD1
35 positive regulation of renal sodium excretion GO:0035815 9.73 DRD3 DRD2
36 dopamine receptor signaling pathway GO:0007212 9.73 DRD4 DRD3 DRD2 DRD1
37 regulation of synaptic transmission, GABAergic GO:0032228 9.72 DRD2 CNR1
38 grooming behavior GO:0007625 9.72 DRD2 DRD1
39 G protein-coupled receptor internalization GO:0002031 9.72 DRD3 DRD2
40 striatum development GO:0021756 9.72 DRD2 DRD1
41 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.72 DRD4 DRD3
42 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.72 DRD5 DRD3 DRD1
43 response to cocaine GO:0042220 9.72 DRD5 DRD3 DRD2 DRD1 CNR1
44 regulation of potassium ion transport GO:0043266 9.71 DRD3 DRD2
45 regulation of dopamine metabolic process GO:0042053 9.71 DRD4 DRD1
46 peristalsis GO:0030432 9.71 DRD2 DRD1
47 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD4 DRD3 DRD2
48 mating behavior GO:0007617 9.7 DRD5 DRD1
49 cellular response to catecholamine stimulus GO:0071870 9.7 DRD5 DRD1
50 cerebral cortex GABAergic interneuron migration GO:0021853 9.7 DRD2 DRD1

Molecular functions related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.97 HTR2A GRM3 DRD5 DRD4 DRD3 DRD2
2 drug binding GO:0008144 9.65 HTR2A DRD4 DRD3 DRD2 CNR1
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.5 DRD4 DRD3 DRD2
4 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
5 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.4 DRD5 DRD1
6 dopamine binding GO:0035240 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
7 dopamine neurotransmitter receptor activity GO:0004952 9.02 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Schizophreniform Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....